These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 8221683)

  • 1. High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines.
    Emons G; Ortmann O; Becker M; Irmer G; Springer B; Laun R; Hölzel F; Schulz KD; Schally AV
    Cancer Res; 1993 Nov; 53(22):5439-46. PubMed ID: 8221683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines.
    Emons G; Schröder B; Ortmann O; Westphalen S; Schulz KD; Schally AV
    J Clin Endocrinol Metab; 1993 Dec; 77(6):1458-64. PubMed ID: 8263128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of the messenger RNAs for luteinizing hormone-releasing hormone (LHRH) and its receptor in human ovarian epithelial carcinoma.
    Irmer G; Bürger C; Müller R; Ortmann O; Peter U; Kakar SS; Neill JD; Schulz KD; Emons G
    Cancer Res; 1995 Feb; 55(4):817-22. PubMed ID: 7850795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers.
    Gründker C; Völker P; Schulz KD; Emons G
    Gynecol Oncol; 2000 Aug; 78(2):194-202. PubMed ID: 10926802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone.
    Yano T; Pinski J; Radulovic S; Schally AV
    Proc Natl Acad Sci U S A; 1994 Mar; 91(5):1701-5. PubMed ID: 8127868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein alpha(I)-mediated activation of phosphotyrosine phosphatase.
    Gründker C; Völker P; Emons G
    Endocrinology; 2001 Jun; 142(6):2369-80. PubMed ID: 11356684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Luteinizing hormone-releasing hormone (LHRH) inhibits apoptosis induced by cytotoxic agent and UV-light but not apoptosis mediated through CD95 in human ovarian and endometrial cancer cells.
    Günthert AR; Gründker C; Böttcher B; Emons G
    Anticancer Res; 2004; 24(3a):1727-32. PubMed ID: 15274347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Receptors for luteinizing hormone-releasing hormone (LHRH) in Dunning R3327 prostate cancers and rat anterior pituitaries after treatment with a sustained delivery system of LHRH antagonist SB-75.
    Srkalovic G; Bokser L; Radulovic S; Korkut E; Schally AV
    Endocrinology; 1990 Dec; 127(6):3052-60. PubMed ID: 2174343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Luteinizing hormone-releasing hormone induces JunD-DNA binding and extends cell cycle in human ovarian cancer cells.
    Günthert AR; Gründker C; Hollmann K; Emons G
    Biochem Biophys Res Commun; 2002 May; 294(1):11-5. PubMed ID: 12054733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines.
    Westphalen S; Kotulla G; Kaiser F; Krauss W; Werning G; Elsasser HP; Nagy A; Schulz KD; Grundker C; Schally AV; Emons G
    Int J Oncol; 2000 Nov; 17(5):1063-9. PubMed ID: 11029513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection and partial characterization of receptors for [D-Trp6]-luteinizing hormone-releasing hormone and epidermal growth factor in human endometrial carcinoma.
    Srkalovic G; Wittliff JL; Schally AV
    Cancer Res; 1990 Mar; 50(6):1841-6. PubMed ID: 2155060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogues.
    Völker P; Gründker C; Schmidt O; Schulz KD; Emons G
    Am J Obstet Gynecol; 2002 Feb; 186(2):171-9. PubMed ID: 11854630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Internalization of cytotoxic analog AN-152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell lines independent of multidrug resistance-1 (MDR-1) system.
    Günthert AR; Gründker C; Bongertz T; Schlott T; Nagy A; Schally AV; Emons G
    Am J Obstet Gynecol; 2004 Oct; 191(4):1164-72. PubMed ID: 15507937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation.
    Gründker C; Günthert AR; Millar RP; Emons G
    J Clin Endocrinol Metab; 2002 Mar; 87(3):1427-30. PubMed ID: 11889221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Luteinizing hormone-releasing hormone induces nuclear factor kappaB-activation and inhibits apoptosis in ovarian cancer cells.
    Gründker C; Schulz K; Günthert AR; Emons G
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3815-20. PubMed ID: 11061544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of novel 68Ga- and 18F-labeled GnRH-I analogues with high GnRHR-targeting efficiency.
    Schottelius M; Berger S; Poethko T; Schwaiger M; Wester HJ
    Bioconjug Chem; 2008 Jun; 19(6):1256-68. PubMed ID: 18510351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct effects of luteinizing hormone-releasing hormone agonists and antagonists on MCF-7 mammary cancer cells.
    Segal-Abramson T; Kitroser H; Levy J; Schally AV; Sharoni Y
    Proc Natl Acad Sci U S A; 1992 Mar; 89(6):2336-9. PubMed ID: 1312718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer.
    Gründker C; Emons G
    Reprod Biol Endocrinol; 2003 Oct; 1():65. PubMed ID: 14594454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Down-regulation and change in subcellular distribution of receptors for luteinizing hormone-releasing hormone in OV-1063 human epithelial ovarian cancers during therapy with LH-RH antagonist Cetrorelix.
    Halmos G; Schally AV; Kahan Z
    Int J Oncol; 2000 Aug; 17(2):367-73. PubMed ID: 10891548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Presence and characteristics of receptors for [D-Trp6]luteinizing hormone releasing hormone and epidermal growth factor in human ovarian cancer.
    Srkalovic G; Schally AV; Wittliff JL; Day TG; Jenison EL
    Int J Oncol; 1998 Mar; 12(3):489-98. PubMed ID: 9472084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.